Clinical trials: GvHD
Opioid-Induced Constipation
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC)in adults taking opioid therapy for chronic non-cancer pain.
- Trial name
- NCT01901328
- Testing
- CB-5945
- Volunteers
- 49 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Acute Leukemia, Hematologic and Lymphocytic Disorder
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
This phase IIa trial studies the side effects of itacitinib when given together with standard treatment (tacrolimus and sirolimus), and to see how well it works in preventing graft-versus-host-disease (GVHD) in patients with…
- Conditions
- Acute Leukemia, Hematologic and Lymphocytic Disorder, Myelodysplastic Syndrome, Primary Myelofibrosis
- Trial name
- NCT04339101
- Testing
- Fludarabine, Itacitinib Adipate, Melphalan
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- City of Hope Medical Center
Disorder Related to Lung Transplantation, Bronchiolitis Obliterans
Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients
This is a single-center pilot study to investigate the efficacy and safety of aerosolized liposomal cyclosporine A in the treatment of chronic rejection in lung transplant recipients with bronchiolitis obliterans syndrome (BOS).
- Conditions
- Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity, Chronic Rejection of Lung Transplant
- Trial name
- NCT01650545
- Testing
- Liposomal aerosol cyclosporine, standard immune suppression, oral
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Maryland, Baltimore
Myelodysplastic Syndrome, Hodgkin's Lymphoma
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
Background: Major problems with stem cell transplantation (SCT) for cancer treatment are a lack of suitable donors for patients without a human leukocyte-antigen (HLA) tissue-matched sibling and graft-versus-host disease (GVHD)…
- Conditions
- Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease, Acute Leukemia
- Trial name
- NCT00520130
- Testing
- Rituximab, Cyclosporine, Allogenic stem cell transplant (ASCT)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)
Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
To evaluate the safety, efficacy and pharmacokinetics of nilotinib over time in the Ph+ chronic myelogenous leukemia (CML) in pediatric patients (from 1 to <18 years).
- Trial name
- DIALOG (NCT01844765)
- Testing
- nilotinib
- Where
- 36 sites in United States, France and 11 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Graft-versus-host Disease
Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)
Rituximab is an attractive agent to bring to the upfront treatment of chronic graft-versus-host disease (cGVHD) due to its favorable toxicity profile, its proven efficacy in the treatment of steroid-refractory cGVHD, and its…
- Trial name
- NCT01161628
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Northside Hospital, Inc.
Psoriasis
Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis
The primary objective of this trial is to evaluate the clinical efficacy and safety of two oral doses of MP1032 (150 mg bid and 300 mg bid) when taken for 12 weeks by patients with moderate-to-severe chronic plaque psoriasis.
- Trial name
- NCT03706209
- Testing
- MP1032
- Where
- 19 sites in Germany, Poland
- Volunteers
- 155 people
- Sponsor
- MetrioPharm AG
Graft-versus-host Disease (GVHD)
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
The purpose of this study was to assess the efficacy of ruxolitinib in combination with corticosteroids in subjects with Grades II to IV steroid-refractory acute graft-versus-host disease (GVHD).
- Trial name
- NCT02953678
- Testing
- Ruxolitinib, Prednisone or methylprednisolone
- Where
- 38 sites in United States
- Volunteers
- 71 people
- Sponsor
- Incyte Corporation
Hepatitis C Virus (HCV)
A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir for an 8- or 12-week treatment duration in participants with chronic hepatitis C virus (HCV) genotype (GT) 5 or 6…
- Trial name
- ENDURANCE-5 6 (NCT02966795)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 84 people
- Sponsor
- AbbVie
Anemia, Kidney Failure
Dynepo Infrequent Dosing Study
The purpose of this study is to demonstrate non-inferiority of efficacy between twice weekly and once weekly dose schedule of Dynepo in previously erythropoietin (EPO)-naive patients, as measured by haemoglobin at week 24 and…
- Trial name
- NCT00450333
- Testing
- Dynepo (Epoetin delta), Dynepo
- Where
- 53 sites in Austria, Belgium and 5 more
- Volunteers
- 407 people
- Sponsor
- Shire
Graft Versus Host Disease, Steroid Refractory GVHD
Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease
Acute Graft Versus Host Disease (GVHD) is a serious medical condition that is a common development after Bone Marrow Transplant (BMT).
- Conditions
- Graft Versus Host Disease, Steroid Refractory GVHD, Acute GVH Disease
- Trial name
- NCT01485055
- Testing
- Infliximab and Basiliximab
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Nationwide Children's Hospital
Chronic Graft Versus Host Disease
Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease
This phase II trial studies efficacy of extracorporeal photopheresis and low dose aldesleukin (interleukin-2) in treating patients with chronic graft-versus-host disease (cGVHD) that does not respond to upfront treatment with…
- Trial name
- NCT03007238
- Testing
- Aldesleukin, Extracorporeal Photopheresis, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Chronic Obstructive Pulmonary Disease (COPD)
A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The purpose of this study is to assess the tolerability (effect of drug on body) and pharmacokinetics (effect of body on drug) of AZD9668 in patients with mild to moderate COPD
- Trial name
- NCT00703391
- Testing
- AZD9668
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Graft vs Host Disease
Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation
Atorvastatin for prevention of acute GVHD
- Trial name
- NCT01175148
- Testing
- Atorvastatin calcium (Lipitor)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- West Virginia University
Bronchiolitis Obliterans Syndrome (BOS), GVHD, Chronic
A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4)
Primary Objective: The primary objective of this study is to assess the tolerability and safety of two dose levels of aerosolized L-CsA vs placebo in addition to SoC therapy for BOS in adult allo-HSCT recipients.
- Conditions
- Bronchiolitis Obliterans Syndrome (BOS), GVHD, Chronic, Stem Cell Transplant Complications
- Trial name
- BOSTON-4 (NCT04107675)
- Testing
- Liposomal Cyclosporine A
- Where
- 17 sites in France, Germany and 1 more
- Volunteers
- 6 people
- Sponsor
- Zambon SpA
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
This phase II trial studies how well cyclophosphamide works in preventing chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant in patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01427881
- Testing
- cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Fred Hutchinson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
This phase II trial studies how well tacrolimus and mycophenolate mofetil works in preventing graft-versus-host disease in patients who have undergone total-body irradiation (TBI) with or without fludarabine phosphate followed by…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00089011
- Testing
- fludarabine phosphate, total-body irradiation, mycophenolate mofetil
- Where
- 5 sites in United States, Italy
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Graft Versus Host Disease
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
To evaluate the safety and efficacy of ibrutinib in combination with prednisone in subjects with newly diagnosed moderate to severe cGVHD.
- Trial name
- iNTEGRATE (NCT02959944)
- Testing
- ibrutinib, Prednisone
- Where
- 102 sites in United States, Australia and 13 more
- Volunteers
- 193 people
- Sponsor
- Pharmacyclics LLC.
Chronic Graft-versus-host-disease
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of KD025 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least 2 prior lines of systemic therapy
- Trial name
- NCT03640481
- Testing
- Belumosudil (KD025)
- Where
- 35 sites in United States
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Kadmon, a Sanofi Company
Severe Aplastic Anemia, Bone Marrow Failure Syndromes
Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia
Our primary objective is to determine if it is feasible for SAA patients to be transplanted using non-myeloablative conditioning and post transplantation cyclophosphamide with partially HLA-mismatched donors.
- Trial name
- NCT02224872
- Testing
- Bone marrow transplant, Thymoglobulin, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins